EVENTIDE ASSET MANAGEMENT, LLC

Holdings History for Celldex Therapeutics, Inc. - Common Stock, par value $0.001 per share (CLDX)

Symbol: CLDX on Nasdaq
Investment type: Equity / Common Stock, par value $0.001 per share
Latest Disclosed Shares Owned: 1,356,186 shares
Security Ownership %: 2%

Shares, Excluding Options vs Price

Value, Excluding Options

Eventide Asset Management, LLC ownership in Celldex Therapeutics, Inc. Common Stock, par value $0.001 per share (CLDX)

14 Aug 2025 - Eventide Asset Management, LLC has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,356,186 shares of Celldex Therapeutics, Inc. Common Stock, par value $0.001 per share (CLDX). This represents 2% ownership of the company. This is the first filing by EVENTIDE ASSET MANAGEMENT, LLC disclosing ownership of Celldex Therapeutics, Inc. Common Stock, par value $0.001 per share (CLDX).

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
Eventide Asset Management, LLC	2%		$30,459,938	1,356,186			$22.46	13G/A	30 Jun 2025	14 Aug 2025, 14:59

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	0.7%	-0.09%	$44,607,415	1,642,559	-216,536	-12%	$27.16	Q4 2025
30 Sep 2025	0.79%	+0.21%	$48,096,095	1,859,095	+502,909	+37%	$25.87	Q3 2025
30 Jun 2025	0.48%	-0.86%	$27,598,385	1,356,186	-2,398,607	-64%	$20.35	Q2 2025
31 Mar 2025	1.4%	+0%	$68,181,159	3,754,793	+1,533		$18.16	Q1 2025
31 Dec 2024	1.7%	+0.19%	$94,842,409	3,753,260	+421,255	+13%	$25.27	Q4 2024
30 Sep 2024	2%	+0%	$113,254,850	3,332,005	+4,873	+0.15%	$33.99	Q3 2024
30 Jun 2024	2.1%	+0.12%	$123,137,155	3,327,132	+208,045	+6.7%	$37.01	Q2 2024
31 Mar 2024	2.1%	-0.34%	$130,908,081	3,119,087	-510,926	-14%	$41.97	Q1 2024
31 Dec 2023	2.3%	+1.3%	$143,966,316	3,630,013	+2,030,013	+127%	$39.66	Q4 2023
30 Sep 2023	0.79%	+0.11%	$44,032,000	1,600,000	+222,260	+16%	$27.52	Q3 2023
30 Jun 2023	0.79%	0%	$46,746,718	1,377,740	0		$33.93	Q2 2023
31 Mar 2023	0.91%	-0.06%	$49,571,085	1,377,740	-85,310	-5.8%	$35.98	Q1 2023
31 Dec 2022	1.3%	-0.29%	$65,208,139	1,463,050	-328,750	-18%	$44.57	Q4 2022
30 Sep 2022	0.99%	+0.19%	$50,367,000	1,791,800	+346,100	+24%	$28.11	Q3 2022
30 Jun 2022	0.83%	0%	$38,976,000	1,445,700	0		$26.96	Q2 2022
31 Mar 2022	0.77%	+0.11%	$49,241,000	1,445,700	+206,800	+17%	$34.06	Q1 2022
31 Dec 2021	0.61%	+0.05%	$47,871,000	1,238,900	+110,900	+9.8%	$38.64	Q4 2021
30 Sep 2021	0.81%	-0.7%	$60,901,000	1,128,000	-980,908	-47%	$53.99	Q3 2021
30 Jun 2021	0.95%	+0.02%	$70,522,000	2,108,908	+46,475	+2.3%	$33.44	Q2 2021
31 Mar 2021	0.63%	+0.07%	$42,486,000	2,062,433	+225,325	+12%	$20.60	Q1 2021
31 Dec 2020	0.5%	+0.36%	$32,186,000	1,837,108	+1,330,929	+263%	$17.52	Q4 2020
30 Sep 2020	0.15%	+0.01%	$7,507,000	506,179	+42,844	+9.2%	$14.83	Q3 2020
30 Jun 2020	0.13%	+0.13%	$6,023,000	463,335	+463,335	NEW	$13.00	Q2 2020

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.